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Twenty years have passed since the beginning of clinical
interventional cardiology on the occasion of the first angio-
plasty procedure performed by Andreas Gruentzig. This disci-
pline, which started as an added technique for physicians who
performed cardiac catheterization, has evolved into a field
recently recognized by the American Board of Internal Med-
icine (ABIM) as deserving a board classification of its own
within cardiology. The certificate of added qualification, re-
cently approved by the ABIM and the American Board of
Medical Specialists, provides the framework for the interven-
tional cardiology examination and the establishment of formal
fellowship programs of the Accrediting Council on Graduate
Medical Education (ACGME). It has been a fascinating 20
years filled with new discoveries, expanded technology and
clinical trials testing the technique against other therapies, and
it has stimulated a dramatically increased interest in vascular
biology. I review many of the events that have shaped inter-
ventional cardiology and speculate on some of the directions in
which we may be headed in the future.
Background for Angioplasty
Andreas Gruentzig is clearly the father of interventional
cardiology; however, he stood on the shoulders of those who
had gone before to make this work possible. J. Willis Hurst, in
compiling the history of cardiac catheterization (1), recounted
some of the benchmarks that tell the story of the development
of cardiac catheterization. In doing so, he selected the individ-
uals who were involved in these events to tell their own story.
Werner Forssmann is credited with performing the first
cardiac catheterization in 1929 (2). He was not looking for a
way to diagnose heart disease but rather for a way to inject
drugs more directly into the right atrium. To do so, he had to
overcome the prohibition of his chief, and he developed an
ingenous way to perform his experiment, as recounted in his
autobiography (3). “I decided to override Schneider’s prohibi-
tion and go ahead with the experiment on my own heart
secretly and quickly. But I needed an assistant, the surgical
nurse. I had to win her over or I would have no access to the
necessary sterile instruments. . . . The following afternoon the
good lady was sitting in her cubicle when I breezed in whistling
cheerfully. ‘Nurse Gerta, I want you to give me a set of
instruments for a venesection under local anesthesia and a
urethral catheter.’
“She started up suspiciously. ‘But no one in the wards is
scheduled for a venesection. You’re not planning to do that
experiment of yours against boss’s orders, are you?’ ‘Nurse
Gerta, you need to know nothing about what I am going to do
but supposing I were to do the experiment—it would be safe.’
“She eyed me closely. ‘Are you absolutely sure there is no
danger?’
“ ‘Absolutely.’
“ ‘Allright then, do it to me. I put myself in your hands.’
“ ‘Well, why not? You’ll be the first person in history to
undergo such an experiment.’ ” Forssmann states that he had
no intention of going through with the experiment on nurse
Gerta, but he did proceed to have her lie down on the
operating table and strapped her arms and legs to the table. He
then proceeded to anesthetize his own arm while distracting
her by applying iodine to her elbow. He describes how, with
one hand, he somehow made an incision over his own antecu-
bital vein, opened the vein and inserted a urethral catheter
about a foot into the vein. Releasing nurse Gerta, he said,
“There we are. It is ready now. Call the x-ray nurse.”
Forssmann then describes how the nurse was yelling at him
because he had deceived her, but she did assist him down the
stairs to the X-ray room, placed him behind the fluoroscopy
screen and performed the X-ray recording. This adventure
gained Forssmann derision and rebuke, but eventually, with
the subsequent contribution of others, he was awarded the
Nobel prize. It is amazing what can be gained by being first in
line.
There was little development in cardiac catheterization in
the ensuing years. Klein, who was from Prague, used catheters
to obtain blood samples to measure cardiac output (4). Later
Andre Cournand and colleagues at Bellevue Hospital in New
York City extended the physiologic measurements (5,6). Much
of this work was an outgrowth of the ravages of World War II
and the necessity of finding ways to study the circulation in
patients who were in shock as a result of blood loss.
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The use of cardiac catheterization for diagnostic purposes
had to wait for the end of World War II. One of the earliest
descriptions of cardiac catheterization for diagnostic purposes
was reported in 1945 by Emmett Brannon, Heinz Weens and
James Warren at Emory University (7). Warren recounted
how they built on the experience of Cournand and Richards at
Bellevue (1):
An agency, the Office of Scientific Research and Development
(OSRD), was set up in Washington as a funding mechanism for
supporting this research. It was under OSRD contract that the
studies at Bellevue were undertaken. Lower Manhattan pro-
vided many casualties that simulated those on the battlefield.
The program was based in the Emergency Room at Bellevue
Hospital. Although highly commendable, this program was not
large enough and efforts were made to establish another focus
of studies on shock. As a result of this, Dr. Alfred Blaylock,
Professor of Surgery at Johns Hopkins, and a group of distin-
guished physicians visited Dr. Eugene A. Stead, Jr., Professor
and Chairman of the Department of Medicine at Emory
University with offices in Grady Hospital. Their mission was
simple. They wished to establish a shock unit at Grady because
its emergency room also had a considerable amount of trauma.
I was particularly enthusiastic about the problem and volun-
teered to go to New York to see the Bellevue operation for
myself.
Warren, Stead and the group continued to make important
contributions regarding cardiac output under various physio-
logic conditions (8), to understand the mechanisms of conges-
tive heart failure (9). Warren recounts (1),
In some way the most exciting thing was the conceptualization
that if an atrial septal defect was present, left to right shunting
of blood through the defect could be detected by appropriate
sampling of blood. The presence of highly oxygenated blood,
which had been through the pulmonary circulation and the right
atrium, gave evidence of shunting even if the catheter did not go
through the atrial septal defect.
A 44-year old man with dyspnea on exertion for 9 years, an
enlarged heart and an accentuated pulmonary closure sound
was suspected of having an atrial septal defect, but the
diagnosis was not certain. Warren recalls the catheterization
(1).
The most exciting moment was when it could be seen after the
catheter had been advanced into the right atrium in a usual way,
but then passed into the left atrium and then headward into
what we presume was pulmonary vein. Blood sample studies for
oxygen content showed the classic and expected configuration.
The difference in color was apparent to the naked eye. There
had been some discussion of what the factors were that caused
flow from the left atrium into the right. It had been suggested
that pressure gradients related to posture might influence
shunting. To test that theory, the patient was tilted in a head
down position and the arterial blood oxygen saturation moni-
tored. If shunting were to be reversed with flow from the right
to the left, then oxygen saturation from the femoral artery
would fall. This did not take place.
Hurst identified Henry Zimmerman from Cleveland as the
first to perform left heart catheterization (10). Zimmerman
recounts his first experience with left heart catheterization (1):
We had a fair idea of what was occurring on the right side of the
heart but could only guess what might be occurring on the left
side of the heart. Dr. Claude Beck and I were discussing some
cardiac problems dealing with the left side lesions and I
mentioned the possibility of catheterizing the left side of the
heart. With one of his residents assisting, we did a number of
dogs, placing the catheter retrograde through an artery in the
leg into the left ventricle. Then after several in-depth confer-
ences, my chief gave the go-ahead to attempt to place the
catheter into the left ventricle of man.
Zimmerman recounts how the catheter was inserted into the
radial artery after being lubricated with olive oil and was
passed retrograde into the left ventricle. The patient had
severe aortic insufficiency, and they discovered that the dia-
stolic pressure in the left ventricle was not elevated, and there
was no systolic gradient on pullback into the aorta.
It is interesting that the development of coronary arteriog-
raphy also occurred in Cleveland (11). Others had attempted
techniques for studying the coronary arteries (12–15). Some
nondirect methods included visualization of the coronary
circulation by occlusion aortography by Charles Dotter (16),
the use of acetylcholine (17), phasic dye injections by Richards
(18) and the use of aortic streaming techniques to alter the
intrabronchial pressure, inducing hypotension and using vari-
ous catheters to opacify the coronary sinuses (19–21). All these
attempts were inadequate, and it remained for Mason Sones to
perform the first direct coronary injections in 1958 and to
report the results at the American College of Cardiology
meeting in Philadelphia the following year (22).
Sones recounts the first coronary arteriogram was inadver-
tently performed in a patient undergoing left heart catheter-
ization (1):
I asked my associate to withdraw the catheter tip across the
aortic valve into the ascending aorta so that we could complete
the procedure by performing an aortogram with the catheter tip
in the ascending aorta. My associate complied and we relied on
the pressure change from the left ventricle to the ascending
aorta without sliding the table top back under the 5 inch
amplifier to confirm the exact location of the tip. I didn’t think
this was necessary because I was quite certain that the catheter
tip lay in the ascending aorta just above the aortic valve. My
associate, Dr. Royston Lewis, made an injection of 40 cc of 90%
Hypaque through the catheter. About one second before the
injection was initiated, I had the switch to initiate a cine run.
When the injection began, I was horrified to see the right
coronary artery become heavily opacified and realized the
catheter tip was actually inside the orifice of the dominant right
coronary artery. I shouted, “Pull it out.” Our combined reaction
times to accomplish withdrawal of the catheter consumed from
3–4 seconds which meant that approximately 30 cc of 90%
Hypaque had been delivered into the right coronary artery. I
was of course horrified because I was certain the patient would
develop ventricular fibrillation. At that time we did not have
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direct current defibrillators and knew nothing about the appli-
cation of closed chest cardiac massage. I climbed out of the hole
and ran around the table looking for a scalpel to open his chest
in order to defibrillate him by direct application of the paddles
of an alternating current defibrillator. I looked at the oscillo-
scope tracing of his electrocardiogram and it was evident that
he was in asystole rather than in ventricular fibrillation. I knew
that an explosive cough could produce a very effective pressure
pulse in the aorta and hoped that this might push the contrast
media through his myocardial capillary bed. Fortunately, he was
still conscious and responded to my demand that he cough
repeatedly. After 3–4 explosive coughs, his heart began to beat
again with initially a sinus bradycardia which accelerated into a
sinus tachycardia within 15 to 20 seconds. He then made a
perfectly uneventful recovery with no neurological deficit or
other sequelae.
Many would have been relieved to escape this apparent
complication, but Sones saw immediately the potential for
coronary arteriography and pursued this technique, thus open-
ing the future for direct coronary bypass surgery and eventually
interventional cardiology.
The development of coronary bypass surgery is well de-
scribed by its most prominent pioneer, Rene Favaloro, in this
supplement to the Journal (23). Favaloro gives credit to Sones,
not only for developing coronary arteriography but also for
training Favaloro himself in the technique and providing the
background that he needed for subsequently developing direct
saphenous vein bypass. Favaloro also gives credit to Garrett for
performing the first coronary bypass procedure as a bailout
during a planned endarterectomy in 1964 (24). He also credits
W. Dudley Johnson, who was the first to demonstrate that
grafting to the distal coronary segments could be performed,
increasing the chance for multiple coronary bypass procedures
(25), and George Green, who pioneered the direct internal
mammary coronary anastamosis (26).
So now, approximately 70 years from the beginning of
cardiac catheterization, 50 years from the use of catheteriza-
tion for diagnostic purposes and 30 years from the advent of
coronary bypass surgery, we are 20 years into the field of
interventional cardiology.
Gruentzig’s ability to develop interventional cardiology was
an outgrowth of these surgical developments enabled by
coronary arteriography and the parallel development of trans-
luminal dilation of peripheral arteries by Dotter (27,28).
Dotter’s genius was not recognized in the United States but
was adopted in Europe by Werner Porstmann in Berlin and
especially by Eberhardt Zeitler at Aggertal Klinik in Engel-
skirchen and later in Nuremberg (29–31). Zeitler, who had
performed a large number of Dotter procedures was the man
who would teach Gruentzig the technique.
Development of Balloon Angioplasty
I have recounted in a previous publication (32) the story of
Andreas Gruentzig’s background, education and early investi-
gational work and only emphasize here the highlights. After
immigrating from East Germany, Gruentzig entered medical
school in Heidelberg and graduated in 1964. After a rotating
internship and a research fellowship in epidemiology, he began
studying peripheral vascular disease at the Ratchow Clinic in
Darmstadt, Germany. It was at this time that he first met
Zeitler, who was speaking about peripheral recanalization by
Dotter’s method. After his move to Zurich as a fellow under
Alfred Bollinger in the angiology department, Gruentzig went
to visit Zeitler to observe the Dotter method. Gruentzig said,
“I not only observed the procedure itself during this time but
also saw the patients before and after treatment and when they
left the hospital I was very impressed with the improvement in
peripheral ankle pressure as measured by ultrasound and by
the fact that the patient was able to walk without any claudi-
cation after successful catheter treatment” (32). Gruentzig
invited Zeitler to Zurich to perform the first procedure at that
institution. Unfortunately, the plaque in the patient’s superfi-
cial femoral artery embolized, lodging distally in the arteries of
the lower leg and obstructing blood flow. Gruentzig mused,
“The radiologists who were skeptical from the very beginning,
now had proof that the method was of no use whatsoever in
human beings” (32). However, Gruentzig persisted with the
method, and with the encouragement of Wilhelm Rutishauser,
he entered cardiology training in the cardiac catheterization
laboratory. Gruentzig was convinced that the technique could
not be applied in the coronary arteries without dramatic
improvements; he said, “Everyone involved in the method at
that time, including Charles Dotter, realized that any applica-
tion of the dilatation procedure to other areas of the body
would require technical changes” (32).
In Berlin, Porstmann had developed a latex balloon with a
slotted angiographic catheter for attempting further expansion
of the peripheral arteries. Zeitler showed this to Gruentzig, but
the system proved to be unworkable (30). Gruentzig set about
to perfect a catheter that would provide a nondistensible
balloon. Working in the evenings with his assistant, Maria
Schlumpf, and her husband, Walter, he tested many versions of
balloons, attaching them with thread and epoxic glue to
diagnostic catheters. The first attempt at nondistensibility
involved the use of a form of silk mesh that would entrap the
expanding balloon. With an interest in finding a very thin
material for the balloon, Gruentzig chose polyvinyl chloride
(PVC) at the suggestion of Hopf, a professor emeritus of
chemistry in Zurich. Through the use of heat molding with
compressed air, Gruentzig formed aneurysmal segments within
the PVC tubing. It was at this moment that he discovered that
the strength of the material was so great that the silk mesh was
no longer necessary as an external constraining element.
The first balloons built were mounted on a diagnostic
catheter. A hole was punctured in the catheter so that the
balloon could be inflated from the main lumen. To prevent the
escape of fluid from the end of the catheter, an occlusion
stylette was passed end to end to block the catheter during
balloon inflation. Gruentzig could not persuade any company
to build a double-lumen catheter, and the occlusion device
catheter was large and bulky. He therefore devised a method
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for replacing the PVC tubing with a distensible segment on the
outside of an angiographic catheter. This created a coaxial
design with the space between the diagnostic catheter and the
PVC tubing serving as a channel for inflating the balloon. The
angiographic catheter with one through-lumen no longer
needed to be occluded.
Maria Schlumpf recounted the long process required to
perfect the double-lumen catheter, which was finally used for
an iliac occlusion on January 23, 1975: “Continued work with
the catheters finally resulted in a system that could be minia-
turized to the size of a coronary artery.” The first experiments
with that catheter were conducted with the help of the surgeon
Marco Turina. A silk ligature was tied around the coronary
artery of a dog, producing a constricting stenosis. On Septem-
ber 24, 1975, these animal experiments were begun and were
subsequently reported at the American Heart Association
meeting in 1976. The responses to Gruentzig’s presentation at
the meeting were not overwhelming (33). However, several
important contributors saw the presentation, including Martin
Kaltenbach, Richard Myler and John Abele. The exhibit was
pointed out to me by Paul Lichtlen, who had been in Zurich in
the early 1970s and who was then chief of cardiology in
Hanover, Germany. My reaction was, “This will never work.”
Nonetheless, this meeting with Gruentzig was crucial to my
eventual conversion to his point of view.
The application of this technique to human coronary arter-
ies would be challenging. To develop the procedure in a safe
manner, Gruentzig insisted it be performed during bypass
surgery so that patients would not be jeopardized. The sur-
geons in Zurich were not enthusiastic about producing com-
petitive flow by dilating a lesion that was about to be bypassed,
but Myler and Gruentzig convinced Elias Hanna, a surgeon at
St. Mary’s Hospital in San Francisco, to assist them with this
endeavor. Hanna indicated that his grafts would “always be
better than what was accomplished with dilatation” (32).
On returning to Zurich, Gruentzig finally had an opportu-
nity to perform his procedure in a patient. This patient had
unstable angina, severe multivessel disease with left mainstem
stenosis and severe peripheral vascular disease. The femoral
arteries could not be intubated, and only the left brachial
artery would allow passage of the catheter to the aorta.
Because of the difficult entry site and cumbersome equipment,
Gruentzig was unable to intubate the coronary artery with the
dilation catheter, and the procedure was abandoned. This
experience radically changed Gruentzig’s mind regarding the
selection of patients for untested techniques. The first success-
ful angioplasty was performed on September 16, 1977. The
patient was 38 years old (the same age as Gruentzig) and had
a discrete lesion in the proximal anterior descending coronary
artery and disabling angina. Bernhard Meier, who as a resident
in Zurich was caring for the patient at the time, recounts that
even though Gruentzig told the patient that he was the first to
undergo the procedure, the patient was enthusiastic to have an
alternative to bypass surgery. With all the senior staff of the
hospital in attendance, Gruentzig performed the procedure
and recalled (1),
The catheter wedged the stenosis so that there was no ante-
grade flow and the distal coronary pressure was very low. To the
surprise of all of us, no ST elevation, ventricular fibrillation or
even extrasystole occurred and the patient had no chest pain. At
this moment I decided not to start the coronary perfusion with
the roller pump. After the first balloon deflation, the distal
coronary pressure rose nicely. Encouraged by the positive
response, I inflated the balloon a second time to relieve the
residual gradient. Everyone was surprised about the ease of the
procedure and I started to realize that my dreams had come
true.
This patient remained free of angina, and when he under-
went recatheterization at Emory on September 16, 1987, the
anterior descending coronary artery was widely patent. Ten
years later, he remains asymptomatic and in September 1997,
he performed a maximal bicycle ergometric test with normal
results. The second successful procedure was performed with
Kaltenbach in Frankfurt. Gruentzig continued to develop the
technique by selecting relatively ideal cases as well as experi-
menting with more challenging situations. By the time he left
Zurich to join our group at Emory University, he had per-
formed 169 procedures. Long-term follow-up of these patients
showed excellent results and a 90% survival rate at 10 years
(34,35).
At the Scientific Sessions of the American Heart Associa-
tion (AHA) in 1977, Gruentzig was to present a paper entitled
“Coronary Transluminal Angioplasty.” It was assumed that he
would be presenting the update of the canine experiments;
however, during the presentation, he reported on the first four
patients who had undergone angioplasty. After describing the
fourth patient, whose left mainstem dilation demonstrated
excellent angiographic success, the audience interrupted the
presentation with applause. Gruentzig said, “I was so surprised
that I almost could not proceed with my 10 minute presenta-
tion. After the lecture, Sones came to me and asked for proof
of my results. I invited him to share with me the cineangiogram
which I had in my suitcase. We went to the exhibition hall and
reviewed the film on this patient together at the booth of one
of the exhibitors” (32).
Dissemination of the Technique
Gruentzig continued to perfect the technique, and patients
came from distant parts of the world to have the procedure
performed. The first American patient recounted his experi-
ence to me. He was having severe angina and saw Lamberto
Bentivoglio in Philadelphia, who told him that there was a new
therapy available. Bentivoglio described percutaneous translu-
minal coronary angioplasty and offered to perform the proce-
dure. The patient was enthusiastic but decided to go to Zurich.
I have subsequently studied the patient; 10 years later, his left
anterior descending coronary artery (LAD) remains visibly
patent with no recurrence of stenosis.
There was understandable enthusiasm, and many wanted to
visit Gruentzig in Zurich to see balloon angioplasty firsthand.
Aleardo Maresta remembers that during his 2-month visit in
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Zurich at that time, Gruentzig was becoming increasingly
uncomfortable with visiting physicians in the catheterization
laboratory. To share his experience in a more organized way,
Gruentzig instituted closed-circuit televised demonstration
courses, the first of which was held in 1978 with 28 physicians
in attendance. In March 1978, Myler in San Francisco and
Simon Stertzer in New York introduced coronary angioplasty
in the United States. The technique spread rapidly; from a few
thousand procedures performed before 1980, more than
30,000 procedures were performed in 1983. Most of the
interest during these early days of angioplasty was in finding
improved ways to use the balloon catheter and ancillary
devices.
Gruentzig’s move to Atlanta started with a conversation
that we had in Zurich in which he expressed his dissatisfaction
with the constraints placed on him in developing the technique
in Zurich. I suggested that he visit us at Emory, and with the
help of Willis Hurst and others, we finally recruited him. John
Douglas and I had been struggling with angioplasty and were
delighted when Gruentzig joined us in October 1980.
Early Angioplasty Equipment
In the early days of angioplasty, the guide catheters were
made of Teflon and were extremely stiff. The balloon catheters
were of a double-lumen design with a closed end and a short
guidewire attached directly to the end of the balloon. There
was no practical way to steer these DG catheters. The catheters
were high profile, and to recross the lesions after dilating them
was considered extremely dangerous. The procedure was
guided by angiographic assessment and by measurement of the
change in pressure gradient across the lesion. Pressures were
measured from the tip of the balloon catheter and from the tip
of the guide catheter. Even though the balloon catheter was
high profile, a significant reduction in gradient could be
documented. In addition, the value of collateral channels could
be determined with the wedged balloon catheter pressure
measurement, which Gruentzig studied extensively (36).
Because of the lack of steerability of the balloon catheter, it
was necessary to achieve selective intubation or at least
selective direction of the guide catheter toward the artery to be
intubated. There was, therefore, great interest in improving the
guide catheters. Techniques were developed for directing the
guide catheter selectively into the anterior descending or
circumflex artery to achieve an adequate platform for passage
of a large-profile balloon catheter (37), to achieve an adequate
backup platform to cross tight lesions with these high profile
catheters (38), for exchanging guide catheters while keeping
the guidewire in the artery (39) and for shaping specially bent
guide catheters to allow access to unusual anatomy (40–42).
Balloon catheters were occlusive and in many cases pro-
duced ischemia. Kaltenbach and colleagues demonstrated ex-
perimentally that inflations needed to be prolonged to 45 s to
completely express fluid from them. Interest grew therefore in
sustaining inflations while maintaining distal flow. Perfusion,
using the patient’s own blood, was achieved experimentally
(43,44) and was applied clinically (45,46). Subsequently, au-
toperfusion balloon catheters with holes proximal and distal to
the balloon allowed flow during balloon inflation (47–50).
These balloons were used for improving the initial results of
angioplasty but more often in coping with complications that
arose during the angioplasty procedure. Maintenance of per-
fusion was a technique used to ensure less ischemia while
moving the patient to the operating room for surgical repair of
the abrupt closure resulting from angioplasty (51). Surgery was
often indicated after failed angioplasty, and techniques for
improving urgent surgical intervention were developed. Close
collaboration with the surgeon took precedence over the
inevitable feeling of competition and resulted in a surgical
mortality rate for failed angioplasty of only 1% at our center
(52–54).
One of the most important developments in guide catheter
technology was the development of the soft-tipped catheters by
Van Tassel and colleagues (55). This technology has since been
adopted by all manufacturers to reduce catheter tip trauma.
In one of the meetings in Zurich, John Simpson approached
me (and probably many others) and asked my opinion regard-
ing his idea of using a guidewire within the balloon catheter as
a rail on which the catheter would travel. The disadvantage
would be the lack of ability to measure pressure adequately
with the guidewire in place, and the advantage would be an
improved ability to direct the catheter through the lesions.
Because no steerable guidewire was available, this seemed a
minor difference from the then available fixed-wire systems.
He told me of his options to start a company that would make
such a device or to sell the idea to some existing companies. I
advised him to sell his idea immediately if someone was willing
to pay for it. Fortunately, he did not follow my advice, and the
over the wire balloons were born. The problem of steerability
remained severe because the wires were cumbersome and
offered little advantage over the previous system.
In 1982, at the urging of Gruentzig and others, companies
began to make steerable guidewires. We used them first in
1982 in one of our courses and found them to be a remarkable
improvement over previous wires. As Patrick Serruys reflected
on the improvements in coronary angioplasty during the past
20 years, he felt the steerable guidewire stands out as the most
dramatic improvement. In an examination of the success and
complication rates at Emory University, I found that after
steerable guidewires became available in 1982 through 1984,
the angiographic success rate increased from 83% to 93%, the
clinical success rate increased from 79% to 91% and the
emergency bypass surgery rate decreased from 7.2% to 2.8%.
Although many improvements have been made in the succeed-
ing years, there has been no greater incremental change in
success and complication rates than that occurring after the
development of steerable guidewires.
During the early days of the guidewire industry, Gruentzig
accompanied the officials of USCI to the Dupont Company.
Dupont manufactured polyethylene terathalate, which is a very
strong noncompliant material. The company did not feel that
making tiny balloon catheters would be a profitable venture
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because the amount of material needed for one 2-liter Coca-
Cola bottle would probably supply USCI for a year! Neverthe-
less, Gruentzig’s persuasive manner prevailed, and the era of
improved balloon materials began. Since then, many additional
improvements have been made to ensure low profile and high
pressure capability in balloon catheters.
As the equipment improved, operators looked for uses
other than lesions in the major coronary arteries. Bifurcation
lesions are very common, and there was great interest in
dealing with these. The so-called kissing balloon techniques
and various modifications were popularized in the early and
mid-1980s (56–64). Others tried to develop better methods for
dilating lesions on curves (65,66).
Several methods of exchanging wires, from short over the
wire systems with extension segments to the long-wire tech-
nique of Kaltenbach, were developed (67). The development
of the monorail systems represents an interesting story in
interventional cardiology. Moving the guidewire from its usual
coaxial position in the catheter was a major departure from
conventional thinking (68–70).
There was a brief departure from guidewire catheters back
to the fixed-wire systems with the development of very low
profile devices. The Hartzler catheter from ACS, the Probe
catheter from USCI and the ACE catheter from Scimed had
no moveable guidewires but were steerable catheters that were
essentially a balloon on the wire itself. These devices filled a
niche until balloon materials and balloon catheter technology
improved and made them usually unnecessary. However, these
“on the wire” balloons still have the ability to cross lesions that
other catheters cannot cross.
Assessment of Angioplasty Outcomes
Evaluation of the early and long-term outcomes of angio-
plasty was a major effort in the early and mid-1980s. A number
of series were examined in registry format. We had the
opportunity to carefully follow up all patients undergoing
angioplasty by Gruentzig in Zurich between 1977 and 1980.
These patients were very symptomatic, relatively young and
had well documented ischemia on stress testing and either
one-vessel disease or a large, high grade culprit lesion in a
single vessel. Gruentzig’s primary purpose in selecting such
patients was, first, to have target lesions that could be treated
with the equipment available at that time and, second, to
document correction of the ischemic insult by decreased
symptoms and improved functional testing. With a grant from
USCI, we were able to follow up these patients completely for
10 years. Maria Schlumpf, Gruentzig’s long-term assistant,
maintained contact with all 169 patients throughout the
follow-up period. The survival rate of patients who underwent
successful angioplasty was 90% at 10 years. Those with true
single-vessel disease had a 95% survival rate. Importantly,
most of these relatively young patients were smokers, and after
angioplasty, most were convinced not to smoke—a factor that
was perhaps also important in their long-term clinical benefit
(34,35). Bypass surgery, for these lesions or progressive lesions
elsewhere, was necessary in 23% of these patients over the
10-year period. Others also have reported encouraging long-
term results after angioplasty (71). We evaluated the long-term
follow-up data of the first 471 patients treated at Emory
University in 1981. These patients had predominantly single-
vessel disease (88%), and the 10-year survival rate was 91%
(72).
Development of Multicenter Registries
Among those who listened to Gruentzig’s presentation at
the 1977 AHA annual meeting was Michael Mock, Chief of the
National Heart, Lung, and Blood Institute (NHLBI) Cardiac
Diseases Branch. Suzanne Mullin Cowley, who worked in data
management in the Cardiac Diseases Branch, remembers that
Mock held an impromptu brown bag lunch with Gruentzig to
discuss the results in the first patients and then returned to
Washington to discuss options with Robert Levy, Director of
NHLBI. In January 1979, a small working group that included
Richard Myler, Simon Stertzer, John Simpson and Peter Block
met with Mock to discuss ways to evaluate the technique.
Early investigators of angioplasty believed that the results
should be carefully documented, and with the help of individ-
uals at the NHLBI, notably Mock, a registry was formed
(73–75). The data center at the University of Pittsburgh,
headed by Katherine Detre, was selected as the core data
center for this first NHLBI PTCA registry. This registry and
the subsequent registry of data collected in 1985 to 1986 (73)
would become important benchmarks for the performance of
balloon angioplasty and for comparison with future interven-
tional techniques. Many others during this time also docu-
mented improving success rates, within the first 1 to 2 years
after the angioplasty began, success rates in the high 80s were
being achieved.
Improving Outcomes
Evaluation of angioplasty was concentrated primarily on
understanding the correlates of successful procedures, compli-
cations and restenosis rates. Most evaluations were performed
in patients with predominantly single-vessel disease or single
culprit lesion interventions (76). The rate for major acute
complications at Emory among the first 3,500 patients (77) was
4.1% and included 2.7% for emergency operation, for myocar-
dial infarction 2.6% and 0.1% for death. The five preproce-
dural predictors of major complications were multivessel dis-
ease, lesion eccentricity, presence of calcium, female gender
and lesion length. However, the greatest predictor was a
postprocedural dissection, which carried a sixfold risk of a
major complication.
The consequence of abrupt closures was also studied. Two
centers evaluated 8,207 consecutive procedures that resulted in
294 acute coronary occlusions (4.4%) (78). The three indepen-
dent variables identified as predictors of death were collateral
channels originating from the dilated vessel (indicating occlu-
sion of other vessels), multivessel disease and female gender.
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An analysis of 32 deaths at Emory, San Francisco Heart and
the University of Michigan Hospitals revealed that the most
common mechanism of death—left ventricular failure due to
vessel occlusion—was correlated with female gender, “jeopar-
dy score” and angioplasty of the proximal right coronary artery
(79).
The major complication at this time was abrupt closure of
the artery, necessitating urgent bypass surgery. This complica-
tion was variously thought to represent coronary spasm, (lead-
ing to the use of calcium antagonists during and after angio-
plasty [80]), dissection (77,81,82) or thrombosis (83).
Restenosis
The restenosis process, initially predicted to occur in ;30%
of patients, became a major problem with angioplasty. Numer-
ous reports of the incidence of restenosis began to appear
(84–91). The pathologic mechanisms of restenosis have been
studied by a number of investigators (92–98). The restenotic
lesion was found to be composed of cells very similar to smooth
muscle cells with a great deal of extracellular matrix (95,98–
106). Various correlates of restenosis were identified in the
guidelines for angioplasty published in 1988 (76). Some of the
conditions associated with an increased rate of restenosis were
coronary spasm (107–110), lesion location (111,112), lesion
morphology (113), serum lipid concentrations (114,115), the
presence of unstable angina pectoris (116–119), lesions with
previous angioplasty (120 –123) and multivessel disease
(124,125). Vein graft lesions had the greatest restenosis rate,
followed by the LAD, particularly the proximal LAD, with the
circumflex and right coronary arteries having lower restenosis
rates (126). Other correlates of restenosis were percent steno-
sis before (126) and after angioplasty (127,128), lesion length
and the translesional pressure gradient after balloon angio-
plasty (129).
Reported restenosis rates in the 1980s varied considerably
from 12% to 53%. Much of this variation depended on the
number of cases restudied. The higher the restudy rate, the
lower the restenosis rate, because symptomatic patients tend to
present for repeat angiograms more frequently. In a landmark
report, Nobuyoshi et al. (130) documented the time course to
restenosis in patients undergoing serial angiography. Although
there was infrequent restenosis at 1 month, most had occurred
by 3 months, although some restenosis continued to occur at 6
months and beyond (130).
In an effort to control the restenosis process, our group and
others attempted to alter the balloon angioplasty procedure to
achieve an improved long-term result (131–134). However,
restenosis rates seemed to be independent of operator tech-
nique and procedural alterations.
Early randomized trials addressed the problem of resteno-
sis by comparing anticoagulation regimens (83,135–139). Al-
though antiplatelet agents were effective in preventing acute
complications (137,138), none of these studies showed that
antiplatelet or anticoagulant strategies influenced restenosis
rates. Other clinical trials of agents such as fish oil (omega-3
fatty acids) had mixed results (140–145); however, this ap-
proach has not been adopted. Corticosteroids applied in
several trials, notably the Multi-Hospital Eastern Atlantic
Restenosis Trial (M-HEART) (146) and a single-center study
(147), failed to show benefit. Antimitotic agents were proposed
(148,149), as was colchicine (150). Vasoactive compounds,
such as calcium channel blocking agents, have been used
without significant effect (80). Angiotensin converting enzyme
(ACE) inhibitors were found to suppress the vascular response
to injury in a rat carotid model (151), and that finding led to
two large multicenter trials of ACE inhibition, both of which
were negative (152,153). Angiopeptin, a somatostatin analog,
also showed potential for antiproliferative activity (154). An
initial clinical trial was promising; however, larger trials proved
negative. With the advent of powerful HMG coenzyme A
reductase inhibitors, a dramatic lowering of serum cholesterol
levels could be achieved. This method was tested in a con-
trolled, randomized trial of lovastatin that resulted in a dra-
matic decrease in cholesterol levels but no change in the
incidence of restenosis (155). Subsequently, two other trials of
HMG coenzyme A reductase inhibitors were conducted that
showed the same negative result (156,157).
Although no compound has been documented in large
randomized trials to reliably reduce the restenosis rate, several
have recently provided some hope. Trapidil, helpful in the
rabbit model (158), is purported to inhibit the effects of
platelet-derived growth factor and was associated with a sig-
nificant reduction in restenosis in a small trial in Japan and in
another, the Study of Trapidil Versus Aspirin in Coronary
Restenosis (STARC) II trial, in Italy (159). An expanded trial
of 1,200 patients is under way (Maresta A, personal commu-
nication, September 1997). Likewise, probucol, an antioxidant
with low density lipoprotein–lowering effects, has shown en-
couraging results. In our laboratory, probucol was investigated
along with lipid-lowering agents in the porcine overstretch
restenosis model (160). No effect was found with lipid-lowering
agents, but probucol did result in a significant reduction in
neointimal formation, suggesting that any benefit was due to its
antioxidant properties. One study from Japan (161) and an-
other from the Montreal Heart Institute (162) have shown a
reduction in the restenosis rate only when probucol was given
for 1 month before intervention. Both studies are relatively
small, and further work in this area is needed.
Because of disappointing results with restenosis trials of
systemic therapy, there has been great interest in delivering
drugs locally. Various balloon delivery systems, starting with
the porous balloon and many other versions, have been used in
an attempt to achieve a high local concentration of drugs
(163–166). To date, none of these methods has proven signif-
icantly effective in animal models or patients, possibly because
of their inefficient drug delivery. Perhaps techniques for sus-
taining drug concentration in the arterial wall will be achieved
in the future. Endovascular radiation or brachytherapy is the
latest attempt at local delivery for restenosis prevention.
Animal studies have been dramatically positive, and recent
pilot studies in patients with primary lesions and those with
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restenosis have shown very encouraging results (167,168). Late
lumen loss was virtually eliminated at the 6-month angio-
graphic follow-up. Further randomized trials are under way.
The Move to Treatment of
Multivessel Disease
Although angioplasty of a single lesion that was causing the
ischemic syndrome was the major objective of the initial Zurich
series, 71 of those first patients had multivessel disease. The
procedure was successful in 52 (73%) of the 71 patients, and a
single lesion was dilated in all but 2 patients. The 6-year
survival for those patients was 92%; 17% required repeat
angioplasty and 14% repeat surgery. During long-term
follow-up (.10 years), 54% remained asymptomatic (34,35).
However, most investigators, continued to perform angio-
plasty in patients with single-vessel disease. It was Geoffrey
Hartzler who pushed the envelope in the early 1980s to treat
more patients with multivessel disease (169). In the early to
mid-1980s, Hartzler, through his training courses, encouraged
operators to explore opportunities for treating patients with
multivessel disease, and there was invariably a conflict between
those operators who favored the more conservative and those
the more aggressive approach. Importantly, neither Hartzler
nor Gruentzig entered into controversy on a personal level.
Throughout the 1980s, there were numerous observational
studies in patients with multivessel disease (170–179). These
reports from 1983 to 1988 showed the number of lesions
attempted per patient to range from 1.9 to 2.7 and the
angiographic success rates per lesion from 80% to 92%.
Complications included in-hospital death (0% to 1.9%), myo-
cardial infarction (1.6% to 5.1%) and the need for emergency
operation (1% to 6.4%). The initial registry of coronary
angioplasty was reopened in 1985 and 1986 to collect data on
a more contemporary series of patients now that the practice of
angioplasty had matured (180).
In the NHLBI PTCA Registry of 1,802 patients undergoing
elective angioplasty, 568 (32%) had two-vessel disease, and 395
(22%) had three-vessel disease. Fifty-three percent of patients
with two-vessel disease and 59% of patients with three-vessel
disease underwent multilesion angioplasty. The success rates
parallel those of the other single-center studies, with successful
dilation in 79% of the patients with two-vessel disease and 78%
of the patients with three-vessel disease. At least one lesion
was successfully dilated in .90% of patients with multivessel
disease. That registry has served as a benchmark for future
balloon angioplasty and device experience. The complications
of multivessel angioplasty were further explored by Myler et al.
(181), who classified their patients into those with single
discrete lesions in each of the vessels dilated and those with at
least one complex lesion characterized by long stenoses, total
occlusions, bifurcation lesions, saphenous vein graft lesions or
internal mammary artery stenoses. The only in-hospital deaths
in this study of ;500 patients occurred in the group with the
more complex lesions. The NHLBI PTCA Registry data (182)
correlated hospital mortality with the number of vessels in-
volved. The in-hospital death rate was 0.9% for patients with
two-vessel disease, 2.2% for those with three-vessel disease
and 8% for the few patients with dilated left main coronary
stenoses.
Clinical and angiographic follow-up data were obtained in
numerous studies of patients with multivessel disease through-
out the 1980s (177,183–188). Mean follow-up, which averaged
;2 years, showed that mortality rates were 1% to 8.5%. The
rate of repeat procedures also had a wide range, with 9% to
35% for repeat angioplasty and 6% to 17% for bypass surgery.
In the NHLBI PTCA Registry (189,190), 5-year survival rates
were 93% for patients with single-vessel disease and 87% for
patients with multivessel disease. Subsequent studies of bal-
loon angioplasty performed during the 1980s showed compa-
rable results (191–196).
Improvements in angina were documented by Myler et al.
(197), who reported that among 488 patients with multivessel
disease, baseline Canadian Cardiovascular Society (CCS) an-
gina status was class II in 46%, class III in 42% and class IV in
12%. At follow-up, 97% of the patients were classified as class
I or II. Another study of patients with multivessel disease
followed up for 2.5 years showed that functional class im-
proved in 82% of patients (177).
Completeness of Revascularization
Angioplasty in patients with multivessel disease often re-
sults in incomplete revascularization. Previous surgical experi-
ence led to the conclusion that complete revascularization in
patients undergoing bypass surgery was superior to incomplete
revascularization (198–200); however, this has not been dem-
onstrated with angioplasty. Angioplasty, by its nature, is unable
to provide revascularization as complete as that by bypass
surgery, primarily because of the presence of totally occluded
vessels but also because of the reluctance to dilate less severe
stenoses that would ordinarily be bypassed. Vandormael and
Deligonul (201) collected a series of reports examining the
completeness of revascularization with balloon angioplasty
during the 1980s and found that the incidence of complete
revascularization ranged from 21% to 47% (177,202–207). In
the experience of Vandormael et al (203), only one third of
patients fulfilled the criterion of no residual stenosis .50%,
but when restenosis was redefined as freedom from stenosis
.70%, approximately half of their patients were considered to
have complete revascularization. There has been reluctance to
dilate less severe lesions because of the chance of stimulating
a restenotic process (208). Noninvasive testing is frequently
used with angioplasty to identify physiologically significant
lesions by areas of documented ischemia on exercise thallium
imaging or stress echocardiography (209).
A number of centers have documented improved event-free
survival rates in patients with multivessel disease who could
undergo more complete revascularization (210). A report from
the NHLBI PTCA Registry (211) showed that 127 patients
with complete revascularization fared better than 159 patients
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with incomplete revascularization in terms of death, myocar-
dial infarction and need for bypass surgery. However, the
baseline features of the patients with incomplete revascular-
ization were different from those of patients who could have
complete revascularization. Logistic regression analysis of the
patients in the NHLBI PTCA Registry, adjusting for left
ventricular ejection fraction ,50%, previous myocardial in-
farction, CCS class III or IV angina, age and geometry of the
lesion, showed that the estimates of future death, myocardial
infarction or angina were no longer significantly different
between the two groups. Our group at Emory performed an
observational study in patients with two-vessel disease; 417
patients undergoing coronary angioplasty and 503 bypass sur-
gery were followed up for 5 years. There were multiple
differences in baseline characteristics, including younger age,
less diabetes, less myocardial infarction, less severe angina and
less LAD involvement in the angioplasty group. Completeness
of revascularization was greater in the bypass surgery group, as
indicated by 3.4 grafts/patient, than in the angioplasty group
with 1.5 lesions dilated/patient. After adjustment for baseline
differences, there was no difference in survival between the
bypass surgery and coronary angioplasty groups (212). No
randomized interventional cardiology study to date has com-
pared intentional incomplete revascularization with inten-
tional more complete revascularization. Therefore, all the
observational studies are fraught with significant bias.
The Emory Angioplasty Surgery Trial (EAST), which is
discussed later, did give some insight into the difference
between bypass surgery group patients with more complete
revascularization versus comparable angioplasty group pa-
tients (213). Almost all segments that were obstructed were
bypassed in the surgery group and 71% were bypassed in the
angioplasty group. Protocol-mandated follow-up angiograms
were obtained at 1 and 3 years and showed sustained revascu-
larization in 88% of the targeted segments in the bypass
surgery group versus 59% in the angioplasty group. By virtue of
repeat procedures performed, that difference in percent of
revascularized segments narrowed by 3 years to 87% in the
bypass surgery group versus 70% in the angioplasty group.
When only severe (.70% stenosis) lesions were considered,
the difference in revascularization between the angioplasty and
bypass surgery groups at 3 years became nonsignificant, which
may partially account for the fact that survival between the two
groups was not different at 3 years (214).
There can be little argument that complete revasculariza-
tion is preferred to incomplete revascularization when possi-
ble. However, some of the motivation for complete revascu-
larization with bypass surgery is to avoid the necessity of going
back into the chest should mild lesions progress and for
bypassing totally occluded segments, some of which serve
nonviable myocardium. If these two categories of lesions can
be excluded, then angioplasty represents an opportunity in
many patients to provide initial physiologic revascularization
comparable to that of bypass surgery.
Randomized Trials of Angioplasty
Randomized trials that compared bypass surgery with med-
ical therapy were conducted in the 1970s amid criticism that
angioplasty was being performed in a large number of patients;
however, no direct comparative trials were carried out. Obser-
vational studies continued (215–218), and in the late 1980s,
true randomized trials were begun. Gruentzig conceived of a
comparison of angioplasty versus bypass surgery in the early
1980s but did not believe the technique was sufficiently mature
for a direct comparison until about 1984. Application was
made for a National Institutes of Health grant to support such
a trial, but funding was not provided, and Gruentzig died
without the opportunity to see the results of such comparisons.
Ultimately, EAST was resubmitted and approved for funding
in 1987 and became the first U.S. trial to be launched. EAST
was soon followed by BARI, starting 1 year later. Other trials
were initiated in Europe and South America; to date, nine
randomized trials directly comparing angioplasty and bypass
surgery have been carried out. Clinical outcome at 1 year was
assessed for eight of these trials in a meta-analysis (219).
There was no difference in hospital or 1-year mortality or
myocardial infarction between the angioplasty and bypass
surgery groups. Three of the trials included patients with
one-vessel disease. In those patients, the 1-year mortality rate
was 0.3% for the bypass surgery group patients and 1.9% for
the angioplasty group patients. In the trials involving patients
with multivessel disease, the 1-year mortality rate for the
bypass surgery group was 2.8% and 3.1% for the angioplasty
group. The major differences between these groups was in the
number of repeat procedures. Repeat angioplasty or bypass
surgery was required in 33% of angioplasty group patients and
only 3% of bypass surgery group patients at the end of 1 year.
Some of the lessons learned from these trials are summarized
here.
The EAST trial (213) consisted of 392 patients with mul-
tivessel disease, of whom 40% had three-vessel disease and
60% two-vessel disease. This trial had a protocol of 1- and
3-year follow-up visits, thallium scanning and coronary arte-
riography. The primary end point was a composite of death, Q
wave myocardial infarction or a large ischemic defect found on
thallium scanning. Other end points were death, myocardial
infarction, repeat bypass surgery and repeat angioplasty. Forty
percent of the EAST and BARI patients had three-vessel
disease, and the remainder had two-vessel disease. All were
eligible for both angioplasty and bypass surgery (220). The
results of EAST, which were published in 1994, showed no
difference between angioplasty and bypass surgery regarding
the primary end point or death. The overall survival rate at 3
years was 93.5%; with 5-year follow-up, the overall survival
rate is ;90% with no significant difference emerging between
the angioplasty and bypass surgery groups. The principal
difference between the groups in the EAST trial, as was found
in all the other trials, was the need for repeat intervention. At
the 3-year defined end point of the trial, repeat bypass surgery
had been performed in 1% of bypass surgery group patients
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and 22% of the angioplasty group patients. Subsequent angio-
plasty had been performed in 13% of bypass surgery patients
and 41% of angioplasty group patients. CCS class II or more
severe angina was present in 20% of the angioplasty cohort and
12% of the bypass surgery cohort at 3 years. Seven- to 10-year
follow-up data are now being tabulated to determine whether
any difference in survival will emerge between the two treat-
ment groups. The more complete revascularization of bypass
surgery may be protective over time, or the predicted late
attrition of vein grafts may influence survival and events in the
opposite direction.
The BARI trial included 914 patients randomized to bypass
surgery and 915 to coronary angioplasty (221). This trial was
powered for a primary end point of overall mortality at 5 years.
The survival rate at 5 years was 89.3% for the bypass surgery
cohort and 86.3% for the angioplasty cohort (p 5 0.19). The
initial in-hospital mortality rate was 1.3% for the bypass
surgery group and 1.9% for the angioplasty group. As in the
EAST trial, the incidence of repeat revascularization was much
higher in patients randomized to undergo angioplasty. At 5
years, 8% of the bypass surgery cohort had undergone addi-
tional revascularization procedures compared with 54% of the
angioplasty cohort. The two U.S. trials, EAST and BARI, are
highly comparable, with 40% and 41% of patients having
three-vessel disease and the mean age being ;62 years in both
studies.
The Coronary Angioplasty Versus Bypass Revasculariza-
tion Investigation (CABRI) (222) included 1,054 patients with
multivessel disease. The 1-year mortality rate was 2.7% for the
bypass surgery group and 3.9% for the coronary angioplasty
group. The Randomised Intervention Treatment of Angina
(RITA) trial (223) was a study of 1,011 patients, with the
primary end point of a combination of death or myocardial
infarction at 5 years. In the RITA trial, as opposed to the
EAST, BARI or CABRI trials, half of the patients had
one-vessel disease. The 2.5-year mortality rate was 3.6% for
the bypass surgery group and 3.1% for the angioplasty group.
Subsequent angioplasty was common (31% in the angioplasty
group). Other randomized trials included the German Angio-
plasty Bypass Investigation (GABI) (224) and the Argentina
Randomized Trial of Angioplasty Versus Surgery (ERACI)
(225). Each of these trials included patients with multivessel
disease; again, the 1-year survival rates showed no difference
between angioplasty and bypass surgery.
There are certain limitations to randomized trials of angio-
plasty versus bypass surgery. First, these trials must concen-
trate on a well defined subset of patients, so many patients with
multivessel disease are excluded. To gain knowledge regarding
a broader group of patients, observational studies will continue
to be important.
The second drawback is ordinarily considered the major
strength of randomized trials, that is, any bias in the selection
process is removed. However, physician bias (judgment) based
on features that are not easily measured may be predictive of
outcomes. If that bias is correct, then patients who are
randomly selected will not have the benefit of any preexisting
wisdom regarding treatment selection. It is therefore impor-
tant to maintain registries of eligible but not randomized
patients, as was done for the EAST trial. In that study, in
addition to the 392 randomized patients, 450 patients were
eligible but were not randomized either because the patient or
the referring physician refused. The recorded baseline features
in these patients were remarkably similar to those in the
randomized patients (40% had three-vessel disease and 60%
had two-vessel disease; mean age in both groups was 62 years,
left ventricular ejection fraction was 60%, previous myocardial
infarction had occurred in ;40%, diabetes was present in 22%,
hypertension was present in 52%, congestive heart failure was
present in 3%). Analysis of the angiographic lesions also did
not show dramatic differences. The major variable between the
patients in the randomized trial and those of the registry was
the use of the therapeutic methods. The treatment applied in
the registry patients was largely that selected by the attending
physicians and sometimes that selected by the patients them-
selves. This judgment resulted in most of the patients with
three-vessel disease undergoing bypass surgery and most of the
patients with two-vessel disease undergoing angioplasty (226).
At the end of 3 years, the survival rate for the registry patients
was 96.4% compared with 93.4% for the randomized cohort
(p 5 0.044). Although it is not possible to directly compare
these patients because they are not identical, the excellent
survival in the very similar registry patients cannot be ignored.
It can be argued that the judgment provided by the attending
physicians in making the treatment choice was influenced by
variables that were not directly measured in the trial. One trial,
Angina With Extremely Serious Operative Mortality Evalua-
tion (AWSOME), enrolling patients who are at high risk for
bypass surgery, is being conducted in several Veterans Affairs
hospitals. The question being asked is whether these high risk
patients, including those facing a second operation, managed
with interventional techniques will have a superior outcome
compared with bypass surgery.
Randomized trials of angioplasty versus medical therapy
have been limited. The Angioplasty Compared to Medicine
(ACME) trial (227), conducted in the Veterans Affairs system,
compared 212 patients not in need of urgent revascularization
who underwent assignment to an angioplasty or a conservative
therapy group (227). Most of these patients had one-vessel
disease. No difference could be demonstrated in survival, but,
the angioplasty group patients had a decrease in angina and an
increase in exercise tolerance. A recently completed study, the
Second Randomized Intervention Treatment of Angina
(RITA II) (228), evaluated 1,018 patients with qualifying
conditions that did not necessitate bypass surgery or angio-
plasty who were randomized to an aggressive interventional
approach or continued medical therapy. There was no survival
difference, and the number of repeat procedures remained
relatively low in both groups. The Veterans Affairs Non-Q-
Wave Infarction Strategies in Hospital (VANQWISH) study
randomized 920 patients with a non–Q wave myocardial
infarction to early invasive or conservative treatment. There
was no survival advantage for early invasive therapy (229). The
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results of these studies point to the fact that patients without
severe ischemic syndromes and with predominantly single-
vessel disease cannot expect an improvement in survival with
angioplasty but may have some decrease in angina threshold.
Most important, the initial medical management of these
patients can be carried out safely. Additional trials extending
this concept of vigorous medical management have been
suggested. In one such proposed trial, comprehensive medical
management will be tested, including extremely vigorous at-
tempts at optimizing serum lipid levels. With this medical
management in place, patients will be randomized to a revas-
cularization strategy using interventional means or continued
medical therapy. Support is being provided by the NIH, the
Canadian government, the VA system and industry. It will be
very important in demonstrating the added value of interven-
tions in the era of effective secondary prevention. End points
will include, in addition to survival, freedom from clinical
events, quality of life, functional status and economic consid-
erations.
The most important subset studied in the BARI trial was
patients with diabetes mellitus, who had a superior outcome
when treated surgically. Conversely, patients without diabetes
had identical results when treated medically or surgically. Of
the diabetic patients receiving insulin or oral therapy, those
undergoing bypass surgery had an 80% survival rate at 5 years,
whereas those randomized to angioplasty had a 65% 5-year
survival rate. A recent analysis of cardiac mortality in the
BARI study also shows significant excess cardiac mortality in
the angioplasty group at 5 years; this difference can be
completely accounted for by the patients with diabetes. The
cardiac mortality rate in the diabetic patients treated with
surgery was 8% versus 24% in patients randomized to angio-
plasty. There are several potential explanations for this differ-
ence. Diabetic patients are known to have more restenosis
(230) and more progression of disease than are nondiabetic
patients. Likewise, the diabetic patients are less likely to
perceive angina. These facts point to the necessity for careful
surveillance of diabetic patients, especially those who undergo
less complete revascularization such as that provided by inter-
ventional techniques. Of interest, diabetic patients receiving
medical therapy in the EAST trial (n 5 59) did not have any
difference in 5-year survival rates whether randomized to
angioplasty or bypass surgery (90% in both groups). An
analysis of the baseline differences between the BARI and the
EAST trial patients shows that the BARI trial patients had
somewhat more severe disease, but one other possibility for
the difference exists. The EAST trial patients had a protocol
1-year thallium scan and angiogram and again at 3 years. In
part because of this close surveillance, two thirds of the
angioplasty group diabetic patients underwent further revas-
cularization over the course of their observation. Again, tight
surveillance and assurance of freedom from ischemia are
probably wise in diabetic patients. Whether more careful
glycemic control will improve the outcome of diabetic patients
undergoing interventional and surgical revascularization is
soon to be investigated in the NHLBI-sponsored BARI II trial.
Interventional Therapy in
Myocardial Infarction
Interventional procedures have also been found useful in
three situations after acute myocardial infarction: 1) as an
elective procedure to alleviate ischemia resulting from a
remaining stenosis after an incomplete myocardial infarction;
2) as rescue therapy in patients who have ongoing or recurrent
symptoms in the hours or days after thrombolytic therapy; and
3) in the acute phase as an alternative to thrombolytic therapy.
Early investigations of patients undergoing angioplasty who
had received thrombolytic therapy were begun by Jurgen
Meyer et al. (231), and later work was instituted by Hartzler et
al. (232) as an alternative to thrombolytic therapy in the acute
phase of myocardial infarction.
Trials were performed to evaluate the advantage of the use
of angioplasty after thrombolytic therapy (233–235). No ad-
vantage could be found with this aggressive approach, but in
the much-quoted Thrombolysis in Myocardial Infarction
(TIMI)-II trial, angioplasty was used only in arteries that had
been opened with thrombolysis; totally occluded arteries had
no intervention. The reverse strategy has been recently tested
in a trial soon to be reported. In the Plasminogen Activator
Angioplasty Compatibility Trial (PACT) trial, patients were
studied who underwent thrombolytic therapy and then were
transferred for early catheterization. In this trial, only occluded
arteries were opened, whereas arteries with TIMI grade 3 flow
had no intervention. Angioplasty in the chronic phase after
myocardial infarction remained a matter for individual selec-
tion. The initial TIMI investigation of patients undergoing
angioplasty within 18 to 48 h did not show improvement after
use of the aggressive approach (236,237).
After thrombolytic therapy, many patients do not have
relief of angina or resolution of their electrocardiographic
changes. Reperfusion after thrombolytic therapy occurs in
;55% to 85% of patients (238–240), and the mortality rate in
those whose arteries do not reopen is high. In both the
Thrombolysis and Angioplasty in Myocardial Infarction
(TAMI) 5 trial (241) and the Randomized Evaluation of
Salvage Angioplasty With Combined Utilization of Endpoints
(RESCUE) trial (242), the strategy of rescue angioplasty was
tested. Improved clinical results with angioplasty were demon-
strated in these two small trials.
Of most interest has been the use of angioplasty for acute
evolving myocardial infarction. Three trials that supported this
concept were reported simultaneously (243–246). The compos-
ite survival rate in the angioplasty group was superior to that in
the thrombolytic group. In the largest of these trials, Primary
Angioplasty in Myocardial Infarction (PAMI) (244), the mor-
tality rate in the angioplasty group was 2.6% compared with
6.5% in the thrombolytic group (p 5 0.06). In these trials and
the observational studies of primary angioplasty, the risk of
intracerebral hemorrhage was reduced compared with throm-
bolytic therapy and is one of the major advantages of primary
angioplasty, especially in older patients.
Extrapolation of these results to a larger population was
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investigated in the Global Use of Strategies to Open Occluded
Coronary Arteries in Acute Coronary Syndromes (GUSTO
IIb) trial (247). Although the difference between primary
angioplasty and accelerated tissue-type plasminogen activator
thrombolytic therapy in that study was small, there have been
no studies suggesting that primary angioplasty carries a higher
risk than thrombolytic therapy.
It seems clear from these observations that primary angio-
plasty can be performed with equivalent safety in patients with
acute evolving myocardial infarction. In centers dedicated to
this approach, superior results are usually achieved. However,
the most important elements in myocardial salvage are time to
reperfusion and establishment of adequate flow. Therefore,
thrombolytic therapy should not be delayed when immediate
angioplasty is not available. Ongoing investigations will test the
potential added advantage of combining thrombolysis and
antiplatelet therapy and will investigate whether the adverse
effect of immediate angioplasty is still present in the era of
powerful antiplatelet agents. The large multicenter trial PAMI
Stent is completing its recruitment phase. Results of this trial
should establish whether the addition of stenting to balloon
angioplasty in the setting of acute myocardial infarction can
further improve outcome.
New Devices
Although the balloon remained the primary device for
performing angioplasty, by the late 1980s new equipment
began to emerge. The first of these was the directional
atherectomy device developed by John Simpson. The concept
was based on the idea that actual removal of atherosclerotic
tissue would be superior to compression or dilation of the
artery. This device was used extensively during its preclinical
and postmarketing approval phase for lesions that were judged
to have a poor outcome with the use of balloon angioplasty;
these included aorto-ostial lesions, those with a great deal of
bulky plaque material in large vessels, protected left main
disease (248), bifurcation lesions (249,250) and arteries con-
taining thrombus and plaque material remaining after balloon
angioplasty. Lesions that had a significant amount of calcifica-
tion on the lumen aspect of the artery proved not to be suitable
for this technique (251). This device was also the first to
undergo extensive clinical trials against balloon angioplasty,
including the Coronary Angioplasty Versus Excisional
Atherectomy Trial (CAVEAT) (252) CAVEAT II (a vein graft
study) (253) and the Canadian Coronary Atherectomy Trial
(CCAT) (254). None of these trials showed directional
atherectomy to be superior to balloon angioplasty in reducing
restenosis; in fact, acute complications, primarily non–Q wave
myocardial infarction, were increased with this technique.
One-year follow-up of the CAVEAT trial showed a surprising
excess of deaths in the atherectomy arm, but there was no
relation with postprocedural myocardial infarction (255). As
yet, there is no explanation for this finding, and a subsequent
trial (Balloon versus Optimal Atherectomy Trial [BOAT])
(256) has not shown similar results. In these trials, there was no
attempt to select patients who were uniquely suited for direc-
tional atherectomy and not suited for balloon angioplasty;
therefore, the failure to show any improvement over balloon
angioplasty may have been due in part to the broad selection
criteria. However, there were some positive aspects. The
CAVEAT trial did show improved restenosis rates for a subset
of lesions in the LAD that did not include the ostium (257) but
not in other locations. In contrast, directional atherectomy was
not shown to have a lower restenosis rate in the CCAT trial,
even in treatment of bulky proximal LAD lesions.
I believe the directional atherectomy device still has prom-
ise for certain unique situations, such as the bifurcation of
large coronary vessels in which the disease involves both
branches, particularly the flow divider. One drawback of
atherectomy may have been the failure to remove adequate
amounts of tissue. The BOAT trial (256) used a more vigorous
technique for removal of tissue, followed by balloon dilation to
achieve the largest possible posttreatment lumen. In that study
and in an earlier pilot trial (258), long-term results showed
greater improvement than those for the CAVEAT trial. The
BOAT trial, in which patients were randomized to balloon
angioplasty or optimal atherectomy, resulted in a restenosis
rate at 6 months of 40% in the balloon group and 32% in the
atherectomy group. Despite this improved restenosis rate,
atherectomy is seldom used in most centers because of 1) a
higher non–Q wave infarction rate; 2) a higher cost; 3) a more
tedious and time-consuming procedure; and 4) a perceived
superior outcome in most lesions with stenting. However,
future potentials for directional atherectomy should not be
ignored. A project to combine intravascular ultrasound with
the atherectomy device was very intriguing because it would
allow very complete tissue removal with the safety of removing
only abnormal plaque tissue without damage to the deep wall
structures. Recent observations by Antonio Colombo (person-
al communication, 1997) suggest that directional atherectomy
followed by stenting may result in a very low restenosis rate.
Although this is a time- and resource-intensive procedure, it
warrants further investigation.
Directional atherectomy in saphenous vein grafts was eval-
uated in the CAVEAT II trial. Three hundred five patients
were randomized to balloon angioplasty or directional atherec-
tomy, and although there was greater lumen improvement
initially with atherectomy, the restenosis rates were not signif-
icantly different (45.6% for atherectomy, 50.5% for angio-
plasty). There was less target vessel revascularization in the
atherectomy group, but in an unblinded trial this finding is
difficult to interpret. There were also more Q wave myocardial
infarctions in the atherectomy group (259).
The second atherectomy device to gain approval was the
transluminal extraction catheter (TEC). This device, designed
to circumferentially remove tissue, especially thrombotic and
other friable material, has been used largely in old, degener-
ated vein grafts (260–263). Because of the selection of high
risk thrombotic lesions, complication rates with this device
have been relatively high (245). At some sites, TEC atherec-
tomy has been used to remove thrombus in the setting of acute
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myocardial infarction, and good results have been reported.
Lesions not associated with acute infarction that were more
complex did not seem to show improvement (264,265).
The rotational atherectomy device, which was developed by
David Auth, was designed to selectively ablate firm, fibrotic
and calcific tissue (266–268). This device spins at a high rate of
speed of 150,000 to 200,000 rpm so its diamond-coated burr
can abrade tissue by a mechanism similar to a dental drill. This
device has proved invaluable in the small subset of patients
whose arteries will not open with balloon angioplasty and has
resulted in full expansion of arteries, allowing more precise
stent expansion in other hard, calcific lesions. The device has
also been used extensively in lesions with superficial calcium
and those that are excessively long. Perhaps more than any
other device, successful use is extremely operator dependent.
Differential cutting depends on very slow movement of the
burr through the lesion so excessive pressure is not applied
against the plaque. This generates small particles about the
size of red blood cells that are removed by the reticuloendo-
thelial system. More vigorous advancement produces larger
bits of tissue that may produce microcirculatory obstruction. If
the burr is tightly engaged into an unyielding lesion, it may
result in rotational torsion, which could produce dissection.
Nonetheless, when used properly, acute outcomes have been
encouraging. Unfortunately the studies that have been done so
far, particularly the Excimer Laser, Rotablator and Angio-
plasty Comparison (ERBAC) trial, comparing rotational
atherectomy with balloon angioplasty, have not shown an
improved restenosis rate (261,269–271). The ERBAC trial,
while not showing a significant difference in restenosis between
rotary ablation and the balloon, actually resulted in a higher
revascularization rate in the rotary ablation group (42% vs.
32% for the balloon group). A new trial of 500 patients, the
Comparison of Balloon Angioplasty Versus Rotational
Atherectomy (COBRA) trial, also resulted in a higher resten-
osis rate in the rotary ablation group. The recently completed
Study to Determine Rotational and Transluminal Angioplasty
Strategy (STRATAS) trial will evaluate the strategy of tradi-
tional rotary ablation in one group using burrs with a ratio to
the reference artery of .0.7, followed by standard balloon
inflation, a group of patients undergoing more vigorous rotary
ablation, taking the burr/balloon ratio up to ;0.8, followed by
very minimal balloon inflation.
Laser angioplasty has had a difficult time making inroads
into interventional cardiology. There was enormous enthusi-
asm for laser therapy in the late 1980s, and companies sprang
up utilizing both excimer laser and homium yttrium-aluminum-
garnet (YAG) laser energy (272–274).
These energies are transported down a flexible fiberoptic
bundle catheter and ablate tissue by direct tissue contact at the
end of the fiber bundle. When activated, the laser ablates tissue
by vaporization and by shock waves. The ERBAC trial (269,275)
did not show any advantage for laser with regard to restenosis
rates. The cases treated in the NACI registry also suggested a
higher complication rate when this device was used (261). None-
theless, the laser catheter was used for aorto-ostial lesions
(276,277), undilatable lesions, total occlusions, calcification le-
sions, long lesions and saphenous vein graft disease (278,279).
Some lesions are generally contraindicated for laser therapy
and may result in dissections or perforations, such as those in
very tortuous segments at the site of bends and those that are
severely calcified, contain a significant amount of thrombus or
are located at the site of wide bifurcations (280–285). Reste-
nosis after laser angioplasty was found to be related to the final
lumen diameter at the completion of the procedure (268,286).
Two new applications for laser therapy may be beneficial: 1)
for diffuse restenosis within stents, which is being evaluated in
the Laser Angioplasty for Restenosed Stents (LARS) trial; and
2) use of a very small fiber bundle, referred to as a laser wire,
for crossing chronic totally occluded segments (287). This wire
is being evaluated in the Total Occlusion Trial With Angio-
plasty by Using Laser Guidewire (TOTAL) trial (287), which
has shown in the first 110 patients treated that the success rate
with guidewire attempts was only ;40%, whereas the use of
the laser with or without the guidewire attempts resulted in a
success rate of ;60% (Martin Leon, personal communication,
1997).
Whereas the advent of new devices was greeted with a great
deal of enthusiasm in the late 1980s and 1990s, a comparison of
the New Device for Angioplasty Registry collected between
1990 and 1994 and the NHLBI balloon angioplasty registry of
1985 to 1986 proved very interesting. These registries were
both sponsored by the NHLBI, with the same core laboratory
performing the data analysis. There were many baseline dif-
ferences between the patients treated with the new devices and
those treated with balloons 5 to 7 years earlier. However, after
risk adjustment, overall improvement in 1-year outcome could
not be demonstrated with the new devices. In fact, target lesion
revascularization was actually superior in the patients treated
with balloon angioplasty. Many of the devices produced higher
acute complication rates without improving late results. The
major weakness of this comparison is that only ;10% of the
patients underwent stenting for elective indications. In that
one group, target lesion revascularization was less than that in
the balloon angioplasty group (288).
Stent Era
Coronary stenting has become the most important devel-
opment in interventional cardiology since the development of
the balloon and the steerable guidewire systems. At present,
coronary stents are being used in between 25% and 75% of all
interventional procedures and in some practices even more
frequently.
Stents are endoprosthetic scaffolding devices designed to
enlarge the vessel lumen, seal dissections and create a rounder,
smoother channel. The idea of an endoprosthetic scaffold is
very old. Alexis Carrel suggested the possibility of an endo-
prosthetic device, and Charles Dotter developed “sleeve” graft
devices but never implanted them in patients. The first human
implants of coronary stents occurred in 1986. The stent was the
interwoven helical self-expanding design (Wallstent), which
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was used by Jaques Puel in Toulouse, France and Ulrich
Sigwart in Lausanne, Switzerland. A wire coil stent, designed
by Cesar Gianturco, was implanted at Emory University Hos-
pital in 1987 by our group, and a slotted tube design by Julio
Palmaz was inserted in a patient in Sao Paulo, Brazil by
Richard Schatz and Eduardo Sosa the same year.
Some of these stents were first applied to treat arteries that
become acutely occluded after angioplasty. Others were in-
serted in an effort to reduce restenosis. Currently, more than
40 stent designs have been used worldwide, although until
recently only two were available in the United States. The
Gianturco-Roubin stent, which was approved for general use
by the Food and Drug Administration (FDA) in 1993, was
indicated for abrupt and threatened closure (289–291). In
1994, the Palmaz-Schatz stent was approved by the FDA based
on registry data (292,293) and two pivotal randomized trials.
Patients studied in the Stress Restenosis Study (STRESS) (294)
and the Belgian Netherlands Stent Study (BENESTENT) (295)
underwent single-lesion angioplasty in vessels ranging from 3
to 4mm in diameter and ,15 mm in length. The reduction in
restenosis was from 42% to 32% in the STRESS trial and from
32% to 22% in the BENESTENT trial. Different quantitative
angiographic systems may have been partially responsible for
the lower rates in the European study. After the general
release of this stent, the device was used extensively for other
indications, including long lesions requiring multiple stents,
vessels ,3 mm, bifurcation lesions, vein grafts and ostial and
restenotic lesions. Although the STRESS and BENESTENT
trials showed a significant reduction in restenosis, bleeding
complications were greater in the stent group. Over 3% of the
patients with stents also experienced acute thrombotic occlu-
sion in the days after stent implantation despite extensive use
of heparin and Coumadin (warfarin) and a hospital stay that
averaged ;5 days.
Two major developments revolutionized the use of stents.
Paul Barragan and others in Marseilles, France began to use
antiplatelet therapy consisting of aspirin and ticlopidine exclu-
sively and abandoned the use of warfarin (296). This practice
spread rapidly throughout France and other countries. Anto-
nio Colombo of Milan, Italy, who had invited Jonathan Tobis
from the University of California, Irvine to collaborate on an
evaluation of the results of stenting judged by intravascular
ultrasound, discovered that many times stents were not fully
expanded and were in poor apposition against the vessel wall.
These features were not easily discernible by angiography, and
this observation led to the use of high pressure post-stent
balloon inflations for more complete expansion of the devices
(297). An understanding of the improved results with anti-
platelet therapy was supplied by Schoemig et al. (298). This
study, comparing aspirin and ticlopidine therapy with warfarin
therapy, demonstrated that the platelet activation occurring
with the latter was not present when antiplatelet therapy alone
was used. This is the likely explanation for the improved
subacute thrombosis rate that has been seen in all published
studies using antiplatelet therapy alone. Because of dramati-
cally improved clinical results, consisting of decreased sub-
acute thrombosis rates, reduced bleeding complications and
substantially shorter hospital stays, the practice of using anti-
platelet therapy without continued anticoagulation and the use
of high pressure post-stent balloon expansion became standard
practice. These observations have now been confirmed by
clinical trials (Intracoronary Stenting and Antithrombotic Reg-
imen Trial [ISAR] [299] and STARS [300]). The STARS trial
resulted in a significant reduction in subacute thrombosis
(0.6%) in the aspirin and ticlopidine group compared with that
in the warfarin or aspirin therapy group.
Although stents were evaluated in these trials for a rather
narrow indication, the subsequent use pattern has shown that
there is a widely held belief that stents will also be more
effective than balloon angioplasty in many of the other subsets.
Much of this remains unproved and needs additional evalua-
tion. One recent trial comparing stenting with balloon angio-
plasty in vein grafts showed mildly improved clinical results
and restenosis rates utilizing the Palmaz-Schatz stent (Saphe-
nous Vein De Novo [SAVED] trial) (301). Other evaluations
studying small vessels, long lesions and other subsets are
underway.
Trials comparing second-generation stents with the Palmaz-
Schatz stent for general comparability regarding safety and
efficacy have also been conducted. Several of these designs are
soon to be released in the United States, and others will be
forthcoming in the near future. Improved methods for evalu-
ating these stents in a consistent, cost-efficient manner are
needed, and collaboration between the profession, the FDA
and industry should significantly improve procedures in the
future. Efforts to reduce the time to approval for safe devices
are underway involving the American College of Cardiology,
the FDA and industry applicants.
Issues to be resolved are the following: What evaluation
process should new but similar stents have before release?
What role can standardized bench testing have? Can registry
data demonstrating that a new stent can reach certain bench-
marks for safety and restenosis suffice? Will off-label use be
addressed? What role should industry play in supporting
expanded clinical investigation of stents in small vessels, long
lesions, and so forth? Should evaluation of such anticipated
broader application of stents be part of original submissions?
The cardiology community can contribute greatly to finding
appropriate answers for these and other questions. These
conversations are ongoing.
Important questions regarding stenting remain. The first is
whether stenting should be used in most lesions or whether it
should be limited to subsets in which it is demonstrated to be
preferable to other techniques regarding outcomes. An obser-
vation from the BENESTENT trial was that patients under-
going balloon angioplasty with excellent results did not have a
significantly higher restenosis rate than patients receiving
stents (Serruys P, personal communication, March 1997).
Further economic analysis of these data suggests that stenting
in the LAD may be cost-saving, whereas stenting in the right
coronary artery may be more expensive than balloon angio-
plasty in the long run. The clinical trials of stenting have
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concentrated on single lesions. However, a large proportion of
patients currently undergoing interventions have multivessel
disease. The previous trials comparing angioplasty with bypass
surgery are now being repeated with the use of stents. Two
trials have begun in Europe. The Artery Revascularization
Therapy Study (ARTS) and Stent or Surgery (SOS) trials are
designed as strategy trials to evaluate patients with multivessel
disease randomized between interventional techniques, includ-
ing the use of stents versus a strategy of direct bypass surgery.
End points will be similar to those in previous trials, such as
EAST, BARI and CABRI, and will include death, myocardial
infarction and the necessity for repeat interventions. Whether
these trials can improve on the excess late reintervention in the
stent arm remain to be seen. If stents reduce restenosis in a
large number of lesions, then an improvement should occur.
Because the type lesions that will be stented will not be limited
to those in the STRESS and BENESTENT trials, the degree of
improvement in restenosis rates cannot be anticipated. To the
extent that repeat interventions are driven by progression of
disease or incomplete revascularization, stenting will not alter
the results.
Meanwhile, many additional stents are soon to be approved
and released in the United States. This will be a very important
development because earlier stents were difficult to place in
many situations, and the availability of lower profile, more
flexible stents of varying lengths should improve results. Be-
cause improved stents may allow for placement in more
diffusely diseased arteries, it is possible that restenosis rates
will actually go up, and therefore the value of continued
progressive clinical evaluation cannot be overemphasized.
The major drawback of stents at the present time is the
occurrence of neointimal proliferation and matrix formation
within the stent (302–304). Although the restenosis rate may
be reduced by stenting, if restenosis does occur it is a much
more serious consequence than restenosis developing in a
segment that has not been stented. In-stent restenosis has
carried a re-restenosis rate that has been variously reported as
ranging between 25% and 65%. Techniques for treating in-
stent restenosis, including debulking with laser or Rotablator
and restenting residual disease, have been advocated by some.
One series primarily using balloon angioplasty was associated
with a relatively low repeat intervention rate (305), but few
have been able to duplicate this experience. An important
determinant of the results of angioplasty for in-stent restenosis
seems to be the diffuseness of the restenotic process. Endovas-
cular brachytherapy was recently reported by Teirstein et al.
(306). In a group of 53 patients with in-stent restenosis
randomized to repeat dilation with or without endovascular
brachytherapy, the group with active treatment had a signifi-
cantly reduced restenosis rate and late loss in lumen diameter.
These studies used gamma irradiation and are being repeated
by others using the safer beta irradiation (307,308). Positive
results may allow radiation therapy to be delivered safely
during routine catheterization procedures.
Adjunctive Equipment and Therapies Used
in Angioplasty
A number of devices have been developed to aid in the
evaluation of arteries, in selection of therapies and in perfor-
mance of the procedures. Prominent among these is intravas-
cular ultrasound, which can give an image of the arterial wall
that is not available by angiography. Characteristics, such as
lumen size and contour, amount of plaque, the true size of the
external dimension of the artery, and the presence and distri-
bution of calcium deposits within the artery are readily ascer-
tained. This technique is used in selecting patients for devices
such as rotary ablation when calcium is present, for sizing
balloons and stents and when evaluating the result of therapy
to decide whether further interventions are necessary. Al-
though used extensively in some centers, ultrasound remains
an expensive addition to the armamentarium, and its added
value is currently being evaluated (309–312). Fiberoptic an-
gioscopy can give accurate information regarding the presence
of thrombus but is seldom used clinically.
Two methods of assessing the physiology of coronary flow
have been developed: 1) the Doppler flow wire, which can
record the velocity of blood flow in the coronary artery and
thereby establish whether lesions are impeding the flow of
blood (313). Measurements across lesions can show increased
velocity and turbulence and, in combination with measure-
ments of the arterial dimension, can lead to assessment of flow.
This technique has been validated against angiography and
ultrasound examinations and has a potential future in assessing
borderline lesions and guiding therapy. 2) Direct coronary
pressure measurement can be performed with balloon cathe-
ters, but the bulk of the catheter adds artifact to the measure-
ment. Studies from our group (314,315) showed that the
gradient was an important predictor of acute results and
restenosis. Recently, small-bore fluid-filled guidewires have
been developed, and catheter-tipped manometers on guide-
wires as small as 0.014 in. allow accurate measurements of
pressure across coronary stenoses (316). The use of direct
pressure measurements and velocity determinations during
maximal pharmacologic vasodilation allow assessment of the
degree of coronary flow impairment, which may not be ob-
tained by angiography alone. These techniques undoubtedly
will be refined and should be helpful for management of
patients in the future.
The most interesting pharmacologic adjunct to angioplasty
has been the introduction of potent antiplatelet agents, in
particular, the glycoprotein IIb/IIIa blockers. Compounds that
are antibodies, peptides or small molecule nonpeptides have
been developed, and one (abciximab), a C7E3 antibody frag-
ment, has been released for clinical use. This drug, tested in
patients with a recent myocardial infarction and unstable
angina pectoris, has shown significant reduction in acute
ischemic complications (317,318). Other nonantibody drugs
(tirofiban and integrilin) have also shown similar effects in
trials (319,320). None of the IIb/IIIa trials confirm any effect
on restenosis, but the effect on reducing acute thrombotic
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complications has been impressive. Currently, these drugs
remain expensive, and the added value to heparin and less
costly antiplatelet therapies remains to be elucidated.
Because the role of platelets has been clearly defined in
interventional procedures, and these antiplatelet agents are
potent inhibitors of platelet aggregation, it would stand to
reason that they will be important adjuncts. Cost is currently
the major constraint, and it is likely that costs will come down
with competition among the agents. The clinical safety and
effectiveness of sustained antiplatelet activity are being evalu-
ated in trials of oral IIb/IIIa compounds. Whether these will
alter the course of patients in the long term is of significant
interest. Will other compounds, such as specific antithrombins,
or less expensive agents, such as aspirin and ticlopidine, or the
newer agent clopidogril compete favorably? The newest play-
ers in the antithrombotic competition involve blocking the
tissue factor pathway. The development and testing of these
agents will continue to link interventional cardiology and
hematology in productive investigation. Another contributor
to platelet activation is the use of nonionic contrast agents
(321). We believe that nonionic contrast agents should be
avoided when possible to reduce the incidence of thrombotic
complications (322,323).
Contribution of Coronary Angioplasty to
Vascular Cell and Molecular Biology
The phenomenon of vascular healing in response to me-
chanical injury was investigated well before the advent of
coronary angioplasty. Early studies attempted to mimic the
spontaneous intimal lesions of arteriosclerotic disease by var-
ious means, including endoluminal placement of sutures (324–
326), adventitial electrocautery (326,327), ligation (328) and,
later, embolectomy catheter deendothelialization (329–331).
These essential and groundbreaking studies defined the mor-
phology, time course and basic pathologic mechanisms of
arterial wound healing, including determinations and condi-
tions of platelet and fibrin accumulation, inflammation,
smooth muscle cell proliferation, reendothelialization and
intimal lesion formation. Because so many of these studies
pointed to the similarities of “spontaneous” atherosclerotic
disease with the mechanical loss of endothelium, the “response
to injury” hypothesis of atherosclerosis was formed, which
remains a central tenet of the way in which coronary and
peripheral arterial lesion formation is viewed (332). The work
of Keith Robinson and his team in our research laboratory has
long convinced me that restenosis after angioplasty is a wound-
healing phenomenon (100).
More recently, the field of vascular biology has fairly
exploded with vast accumulations of information, much of it a
consequence of new molecular techniques to identify, se-
quence and target certain genes, genetic messages or protein
products that influence the milieu of an injured and healing
artery (333–337). For example, recent studies of patients
undergoing angioplasty have included explorations of the roles
of osteopontin and aVb3 integrin expression (338), or the
relation between ACE and apolipoprotein E genotypes with
restenosis (339) or the prediction of restenosis based on the
mitogenic activity of plasma (340) from assessment of blood
samples taken at the time of coronary angioplasty. Fervent
activity using animal models parallels these clinical studies in
an effort to identify critical components of the restenosis
process that might be amenable to therapy.
Other advances, such as stents and atherectomy catheters,
have extended the horizons of arterial biologic research to
include biomaterials (in the case of stents) and the application
of histopathologic, immunohistochemical and molecular tech-
niques, such as in situ hybridization and polymerase chain
reaction to human tissue samples (obtained by directional
atherectomy). Examples of studies in which atherectomy sam-
ples have been used include investigations on the role of
cytomegalovirus and its influence on the tumor suppressor
protein p53 (341) ostepontin expression (342) and cell prolif-
eration, apoptosis and histopathologic mechanisms of in-stent
restenosis (343). Furthermore, the fields of localized drug
therapy, polymer chemistry, genetic engineering and brachy-
therapy have recently gained an influx of inquisitive physicians
and scientists who have begun to apply the expertise gained in
these disciplines to the field of arterial interventional therapy
(344–347).
There is a growing body of evidence that reactive oxygen
species (oxygen-derived free radicals) are implicated in the
pathogenesis of restenosis. Several animal studies have dem-
onstrated that administration of antioxidants (radical scaven-
gers) in pigs decreases neointimal formation and increases
overall lumen and vessel size after coronary artery balloon
angioplasty (160,348,349). A recent study demonstrated that
increased superoxide production 2 weeks after balloon injury
in the same model was inhibited by administration of antioxi-
dant vitamins (350). Finally, a recent small clinical study
demonstrated a benefit of the antioxidant probucol for reduc-
ing restenosis (351).
Diverse scientific disciplines have made major contributions
to the practice of angioplasty. However, it is the prevalence of
restenosis as well as the sheer numbers of patients undergoing
coronary angioplasty for symptomatic ischemic coronary artery
disease that has driven and continues to drive the research
efforts of many investigators who are exploring the basic
mechanisms of vascular biology in search of new therapies.
The Discipline of Interventional Cardiology
Initially, balloon angioplasty was available only to those
who would commit to recording data and cooperating with
national registries. Later, the technique became available to all
cardiologists who wished to apply it in their patients. In 1988
and again in 1993, the American College of Cardiology issued
guidelines on indications for coronary interventions (76,352).
Included in those guidelines were recommendations for ap-
proximate activity levels considered necessary to achieve and
maintain competence. These recommendations have been
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controversial, and recently a number of studies have been
performed to try to identify the relation between operator
activity and outcomes (353–355). New recommendations are
being generated based on this and other evidence in an effort
to improve outcomes. However, credentialling to perform
interventional procedures is entirely a local matter to be
determined by the hospital in which one practices. Many have
discovered that consolidation of experience among smaller
numbers of operators within groups has been an effective
strategy. This achieves a higher level of experience, which is
necessary as interventional procedures become more and more
complex and the knowledge of new innovations becomes
critical. The participation in the selection of interventional
procedures by colleagues who do not perform these techniques
can also be helpful in diffusing the concern about self-referral.
A quick solution to the problem of an oversupply of operators
performing angioplasty is not immediately attainable, but there
is pressure to consolidate and improve quality. Undoubtedly,
heightened surveillance of performance of all medical proce-
dures will be part of our future, and it is crucial that the
profession participate to the greatest extent possible in devel-
oping rational guidelines.
Much of the expanding knowledge base in interventional
cardiology is being developed through the mechanism of
ongoing randomized clinical trials. Some of these will be
structured to look at surrogate end points, such as restenosis
rates. However there is an increasing emphasis on clinical
outcomes, which is appropriate. Topol et al. (356) emphasized
some of the problems in clinical trial design in an excellent
review. They stressed the importance of death and myocardial
infarction as a robust end point for these trials. However, one
should remember that coronary interventions seldom result in
death but often produce creatine kinase (CK) elevations
recorded as infarction. The evidence regarding the prognosis
of CK elevations in the moderate range without Q waves,
documented vessel reclosure or emergency surgery is still
controversial, and much more information is needed before
combining these events with death as the reference standard.
Carefully designed and executed randomized trials will be
necessary to answer many questions, and carefully controlled
registries will be appropriate for others. The challenge will be
to thoughtfully judge which method is sufficient and cost-
effective.
Because of the exploding knowledge base underlying the
discipline of interventional cardiology, the ABIM has ap-
proved a certificate of added qualification (CAQ) in interven-
tional cardiology. This will be the second such CAQ approved,
the other being for cardiac electrophysiology. The purpose of
the CAQ will be to recognize those who are bona fide
practitioners and consultants in interventional cardiology and
therefore will ultimately require completion of a minimum of
1 year of interventional cardiology training within an ABIM-
approved fellowship program. This training will be in addition
to the usual 3-year cardiology program. The examination will
initially also be open to those who have been actively engaged
in interventional cardiology and have performed a substantial
number of procedures. It is important to point out that
certification of this sort does not imply credentialling at the
hospital level. Credentialling entitles one to practice. Certifi-
cation is a recognition of satisfactory completion of training
and an examination and is designed to recognize that achieve-
ment.
Specific requirements for sitting for the examination are
being developed by the ABIM for the first examination to be
given in late 1999. The American College of Cardiology and
the Society for Cardiac Angiography and Interventions are
developing a joint board review course to assist in preparation
for this examination.
Conclusions
Interventional cardiology has sprung from its infancy
through a turbulent adolescence and is now approaching
maturity. Because of dramatic technologic developments,
many patients can now undergo appropriate revascularization
procedures much less obtrusively than was possible in the past.
With this enhanced technologic prowess must come reasoned
judgment in the management of patients. A maturing disci-
pline demands well trained, highly motivated and experienced
operators to fulfill its greatest potential. Innovations and new
discoveries are not completed but are just beginning. The
science of vascular biology and its lessons are being learned by
the interventional cardiologist. The potential for altering heal-
ing responses through an understanding of pharmacologic and
physical agents that act on genetic signals may change the
interventionalist’s fixation on simply mechanical and geometric
improvements. In the final analysis, it will be patient outcomes
that determine the success of our efforts. These will not be
determined by interventional cardiology in isolation but
through application of appropriate therapies at the appropri-
ate times, be they medical, interventional or surgical. Perhaps
in the millenium to follow, this revolution in management of
the world’s leading cause of death stimulated by Forssmann,
Cournand, Sones, Favaloro, Dotter, Gruentzig and many
others will translate, through the efforts of our scientific
colleagues, to a solution for atherosclerosis itself.
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